Monoclonal antibody 8H9 I-124 - Y-mAbs Therapeutics

Drug Profile

Monoclonal antibody 8H9 I-124 - Y-mAbs Therapeutics

Alternative Names: 124I-8H9; 124I-8H9 (B7-H3)

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; Weill Cornell Medical College
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action CD antigen modulators; Immunostimulants; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glioma

Most Recent Events

  • 18 Nov 2016 The US FDA grants Y-mAbs Therapeutics a rare pediatric disease designation for 8H9I-124 for the treatment of diffuse intrinsic pontine glioma
  • 09 Sep 2016 Phase-I/II clinical trials in Glioma in USA (Infusion) (Y-mAbs Therapeutics pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top